LAV leads $23m funding in Targeting One and 18 more deal updates from Greater China
LAV leads $23m funding in Targeting One and 18 more deal updates from Greater China ResearchPremium PCR-based disease detection firm Targeting One has secured 150 million yuan ($23 million) in its Series B round of financing led by life sciences-focused investment firm Lilly Asia Ventures (LAV), the lead investor said on a WeChat post on Friday. New investors Hillhouse Capital’s venture unit GL Ventures and China Growth Capital and return backers Jufeng S&T Venture Investment’s joint fund Qingdao Yufeng Investment, Chongyuan Huichen Ventures, joined the...
Source: dealstreetasia.com